Maarten De Château

Maarten is a bio-entrepreneur working primarily in oncology and rare diseases. He did basic research at Lund University, Harvard Medical School and Uppsala University. He worked as a sell-side analyst at two investment banks: Aragon and Swedbank Markets. For the last 15+ years he has been involved in clinical development at Sanofi and Sobi, before co-founding Cormorant Pharmaceuticals. Cormorant brought a mAb against IL-8 into the clinic as an immune-oncology agent and was sold to BMS in 2016. In the same year he co-founded Buzzard Pharmaceuticals, where a potent IL-1 inhibitor is being developed as an immune oncology agent. He also serves as CEO of Sixera Pharma, developing a NCE treatment for the rare skin disease Nethertons, and is VP Medical Strategy and Innovation at Camurus. He currently also serves on the boards of Atrogi, OxThera, Cavis Technologies and Beactica.

Maarten holds a MD as well as a PhD from Lunds University, Sweden.